Navigation Links
InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
Date:5/25/2011

r 2011 as follows:

  • R&D expense:  anticipated to be in a range of approximately $85 to $95 million.
  • SG&A expense:  anticipated to be in a range of approximately $65 to $75 million.  

Webcast Information – May 26, 8:30 a.m. EDT

To access the webcast of the Analyst Day presentations, investors and other interested parties may log on to the investor relations page of InterMune's corporate website at www.intermune.com.  The company recommends logging on to the site 15 minutes prior to the start of the presentation in order to register or download any necessary software.

About Pirfenidone

Pirfenidone is an orally active, small molecule drug that inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation and differentiation, and plays a key role in fibrosis. It also inhibits the synthesis of TNF-alpha, a cytokine that is known to have an active role in inflammation.

On February 28, 2011, the European Commission (EC) granted marketing authorization for Esbriet® (pirfenidone) for the treatment of adults with mild to moderate IPF. The approval authorizes marketing of Esbriet in all 27 EU member states. Esbriet has since been approved for marketing in Norway and Iceland.

Since 2008, pirfenidone has been marketed in Japan as Pirespa® by Shionogi & Co. Ltd. Pirfenidone is still under investigation for the treatment of IPF in the United States and has not been approved by the U.S. Food and Drug Administration for this use. InterMune currently plans to conduct ASCEND, a new Phase 3 study, toward the goal of bringing pirfenidone to IPF patients in the United States, and currently expects to enroll the first patient in ASCEND in June 2011.

About IPF

Idiopathic pulmona
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. InterMune Receives European Union Approval for EsbrietĀ® (pirfenidone)
2. InterMune Reports Fourth Quarter and Full Year 2010 Financial Results and Business Highlights
3. InterMune to Present at J.P. Morgan Healthcare Conference
4. InterMune Reports Third Quarter 2010 Financial Results
5. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
6. InterMune to Release Second Quarter Financial Results on July 27
7. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
8. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
9. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
10. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
11. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. ... that the applicable waiting period under the Hart-Scott-Rodino Antitrust ... previously announced tender offer by its indirect wholly-owned subsidiary, ... shares of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... , Jan. 14, 2014 The Brandeis Medical Center, led ... a premier and affordable laser tattoo removal experience with ... Brandeis, focus is in providing high quality cosmetic services with cutting ... " Southern California has seen a ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , NEW YORK, Dec. 9 MR, CT, PET - we,ve ... these hi-tech imaging scans? Here,s more on what questions you ... hood with a medical scan. , Listen to this report from ... a division of The NewsMarket. Registered journalists can access video, ...
... , , , INDIANAPOLIS, Dec. 9 ... leading provider of managed voice, Internet and data networking solutions ... that Indiana Blood Center has selected the company to provide ... 11 locations located throughout Indiana. Indiana Blood Center will also ...
Cached Medicine Technology:Indiana Blood Center Taps tw telecom for Data, Internet and IP Telephony Services 2
(Date:7/9/2014)... low back pain are not linked to weather conditions ... precipitation. Findings published in Arthritis Care & Research ... (ACR), indicate that the risk of low back pain ... but was not clinically significant. , According to ... back pain at some point in their life, making ...
(Date:7/9/2014)... in almost all types of cancer sends the protein ... fuel a tumour,s uncontrolled growth, new research suggests. , ... a molecular trigger responsible for ratcheting up activity of ... makes the building blocks cancer cells need to keep ... called SREBP, controls the flow of messages to the ...
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective and ... patients. This is the result of a study led ... for Women,s Gastrointestinal Medicine at The Women,s Medicine Collaborative. ... in advance of print in the American Journal ... C. diff , has increased to epidemic proportions ...
(Date:7/9/2014)... 2014 There has been a sharp increase in ... Center using MyChart, the online, interactive service that allows ... their healthcare providers, schedule appointments, and renew prescriptions. , ... using MyChart each year increased five-fold, while ... than 10-fold, according to a study by Dr. ...
(Date:7/9/2014)... of Allergy and Infectious Diseases (NIAID), part of ... early-stage clinical trial of CRS3123, an investigational oral ... ( C. difficile ) infection. CRS3123 (previously known ... C. difficile growth while sparing normal intestinal bacteria. ... to 30 healthy men and women ages 18 ...
Breaking Medicine News(10 mins):Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... new health reform in China have been released after ... the most important policies ,The National Essential Drug System,. ... high cost of drugs in China through a government-initiated ... that cover a wide range of diseases and meet ...
... today a partnership with Medical Hair Restoration. , ... ... LLC, an online lead generation company, announced today a partnership with ... property, USHairReplacement.com, we wanted to partner with one of the industry ...
... ScarArt is a specially designed temporary tattoo to fit horizontal tummy tuck ... It is waterproof, smear proof and was designed to last 1-3 days. ... ... TX (PRWEB) May 21, 2009 -- ScarArt, an innovative new company specializing ...
... source of information on multiple sclerosis medications and the financial ... ... 21, 2009 -- NeedyMeds, a national nonprofit, added a new resource page ... The page is a multiple sclerosis-specific source of help for those looking ...
... OAK BROOK, Ill., May 21 The University HealthSystem ... 3-year agreement with Mzinga, Inc. for on-demand learning solutions. ... and became effective on March 1, 2009, positions Mzinga ... UHC member hospitals throughout the United States, building on ...
... be associated with obesity. But a new study published ... that the disorder is widely undiagnosed among obese individuals with ... symptoms, but were never diagnosed. , For those with untreated ... existing research shows that it can also mean an increased ...
Cached Medicine News:Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 2Health News:Frost & Sullivan Looks at the Influence of China's New Health Reform on the Pharmaceutical Market 3Health News:The Oro Organization, LLC Partners with Medical Hair Restoration to Launch New Website USHairReplacement.com 2Health News:ScarArt -Creatively Camouflage Abdominal Scars 2Health News:New Source of Information on Multiple Sclerosis Medications 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 2Health News:University HealthSystem Consortium Selects Mzinga for On-Demand Learning Services 3Health News:More than a bad night's sleep 2
BD Vacutainer Citrate Tubes with 3.2% buffered sodium citrate solution are used for routine coagulation studies....
... Cross-match tubes are available ... serum tube contains a clotting ... cross-match tests where serum is ... EDTA cross-match tube is suitable ...
... tubes are available in two ... contains a clotting activator and ... where serum is required for ... tube is suitable where the ...
Inquire...
Medicine Products: